AB1516 APREMILAST FOR TREATMENT OF ORAL APHTOSIS: REAL-WORD DATA MULTICENTER STUDY

Background The main manifestation of Behçet’s disease is oral aphthae. Treatment consists topical corticosteroids and colchicine in recurrent cases. Drugs such as azathioprine, thalidomide, interferon-alpha, tumour necrosis factor-alpha inhibitors or apremilast should be considered selected cases [1] . A phase 3, double-blind, placebo-controlled RELIEF study suggests that an effective agent for the management aphtae benefits were sustained up to 64 weeks. Its onset action occurred within 2 weeks after treatment was started. Adverse events, including nausea, vomiting, diarrhea, more frequently with than placebo [2] It has also been shown psoriasis [3] Objectives To assess effectiveness aphtosis. Methods Retrospective descriptive multicentre patients treated aphtosis associated disease, well who have received another indication (psoriasis) off-label use. Four hospitals participated study. following variables collected: age, sex, diagnosis, at time starting apremilast, response 3 6 months (partial improvement, total lack response, discontinuation due side effects), ESR, CRP, ferritin, 25-OH-Vitamin D, folic acid, cyanocobalamin concomitant (none, corticosteroids, methotrexate, anti-TNF). Descriptive statistics performed using mean standard deviation (SD) continuous quantitative variables. Results 15 being Ten them diagnosed one four Mean age 47.1 ± 12.4 years, 67 % female. All had active apremilast. After treatment, 87 improvement (61.5 partially 38.5 completely resolved); 13 discontinue effects (diarrhea), none response. months, all maintained only two discontinued 12 serological data analyzed (mean SD): ESR 11.4 6.7, CRP 3.7 6.5, ferritin 100.8 167.3, D 31.4 18.9, acid 11.7 9.8, 585.8 527. One patient anti-TNF drug, corticoids five colchicine. Conclusion seems improve aphthae over 87% patients. References [1]Hatemi G, Christensen R, Bang Bodaghi B, Celik AF, Fortune F, et al. 2018 update EULAR recommendations syndrome. Ann Rheum Dis -06;77(6):808-818. [2]Hatemi Mahr A, Takeno M, Kim DY, Saadoun Direskeneli H, Melikoğlu Cheng S, McCue Paris Chen Yazici Y. Apremilast ulcers syndrome 68 weeks: long-term results from a randomised clinical trial. Clin Exp Rheumatol. 2021 Sep-Oct;39 Suppl 132(5):80-87. doi: 10.55563/clinexprheumatol/ra8ize. Epub Oct 6. PMID: 34622764. [3]Stein Gold L, Papp K, Pariser Green Bhatia N, Sofen Efficacy safety mild-to-moderate plaque psoriasis: multicenter, randomized, J Am Acad Dermatol 2022 -01;86(1):77-85. Graph 1. Acknowledgements: NIL. Disclosure Interests None Declared.